Current policies for surveillance and management in women at risk of breast and ovarian cancer: A survey among 16 European Family Cancer Clinics

European Journal of Cancer

Volumn 34, Issue 12, 1998, Pages 1922-1926

  Vasen, H F A ^a   Haites, N E ^b   Evans, D G R ^c   Steel, C M ^d   Moller P ^e   Hodgson, S ^f   Eccles, D ^k   Morrison, P ^g   Lyonet, D Stoppa ^h   Chang Claude, J ⁱ   Caligo, M ^j  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d Sch of Biol and Medical Sciences   (United Kingdom)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f GUY S HOSPITAL   (United Kingdom)

^g N Ireland Regional Genetics Centre   (United Kingdom)

^h INSTITUT CURIE   (France)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j UNIVERSITY OF PISA   (Italy)

^k NONE

more..

Author keywords

BRCA1; BRCA2; Breast cancer; Familial; Surveillance

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL PROTOCOL; ECHOGRAPHY; EUROPE; FEMALE; GENETIC SUSCEPTIBILITY; GYNECOLOGICAL EXAMINATION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; ONCOGENE; ORAL CONTRACEPTION; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0032212512     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00288-3     Document Type: Article

References (25)

1. 1. Newman B, Austin MA, Lee M, King M. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high risk families. Proc Natl Acad Sci USA 1988, 8, 3044-3048.
2. 2. Hall JM, Lee MK, Newmann B, Anderson LA, Huevy B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250, 1684-1689.
3. 3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the 17q-linked breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266, 66-71.
4. 4. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378, 789-792.
5. 5. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in 13q-linked kindreds. Nat Genet 1996, 12, 333-337.
6. 6. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994, 343, 692-695.
7. 7. Easton DF, Ford D, Bishop DT. Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995, 56, 265-271.
8. 8. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336, 1401-1408.
9. 9. Schubert EL, Lee ML, Mefford HC, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997, 60, 1031-1040.
10. 10. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Gen 1997, 61, 120-128.
11. 11. Ford D, Easton D, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62, 676-689.
12. 12. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet 1995, 11, 428-433.
13. 13. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genetics 1997, 15, 103-105.
14. 14. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Cancer 1994, 73, 643-651.
15. 15. Møller P, Maehle L, Heimdal K, et al. Inherited breast carcinoma: prospective findings in 1194 women at risk. Acta Oncol 1996, 35(Suppl. 8), 7-11.
16. 16. Law J. Cancers detected and induced in mammographic screening: new screening schedules and younger women with family history. Br J Radiol 1997, 70, 62-69.
17. 17. Vasen HFA, Beex LVAM, Cleton FJ, et al. Clinical heterogeneity of hereditary breast cancer and its impact on screening protocols: the Dutch experience on 24 families under surveillance. Eur J Cancer 1993, 29A, 1111-1114.
18. 18. Møller P, Maehle L, Heimdal K, et al. Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer. The Breast 1998, in press.
19. 19. Schrag D, Kuntz KM, Garbor JE, Weeks JC. Decision analysis -effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997, 336, 1465-1471.
20. 20. Stephonson J. Study shows mastectomy prevents breast cancer in high-risk women. JAMA 1997, 277, 1421-1422.
21. 21. Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br Med J 1993, 306, 1025-1029.
22. 22. Dorum A, Kristensen GB, Abeler VM, Trop CG, Møller P. Early detection of familial ovarian cancer. Eur J Cancer 1996, 32A, 1645-1651.
23. 23. Tobacman JK, Tucker MA, Kase R, et al. Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer prone families. Lancet 1982, II, 795-797.
24. 24. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives; collaborative reanalysis of data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 1996, 347, 1713-1727.
25. 25. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997, 350, 1047-1059.